Patent · US Active

Anti-ILT3 antibodies and antibody drug conjugates

US12110326B2 · kind B2 · utility

0Cited by

1References

22Claims

0Family size

Assignee

Bluefin BioMedicine, Inc · US

Inventors

Jaime Darce · Arlington, US
Scott Michael Lonning · Westford, US
Nels Eric Pederson · Mansfield, US
Klarisa Rikova · Reading, US
Aleksandr Tkachev · Cambridge, US

Key dates

Filing date	Jan 27, 2022
Grant date	Oct 8, 2024
Priority date	—
Expiry date	Aug 6, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed herein are anti-immunoglobulin-like transcript-3 (ILT3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.